NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
(Total Views: 199)
Posted On: 04/05/2022 3:52:30 PM
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces Q4 and Fiscal Year 2021 Results, Provides Business Update
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries, today announced financial results for the fourth quarter and fiscal year ended Dec. 31, 2021. The company also provided a business update and offered guidance on its strategic changes and growth acceleration planned for FY 2022. “The PCT and BaroFold technologies have provided important early opportunities for commercial traction, as PBI forged scientific understanding and acceptance for its high-pressure platforms,” Jeffrey N. Peterson, chairman of the PBI board, said in the press release. “Building on multiple peer-reviewed opinion leader scientific articles and presentations, accelerating instrument installations, and expanding paid research projects, these platforms are expected to generate important sales growth in 2022 and beyond. In addition, we believe the UST platform is opening up a new, game-changing growth trajectory with its promise for revolutionizing massive global markets from pharmaceuticals, nutraceuticals, cosmetics, agrochem, food/beverage processing, and more.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries, today announced financial results for the fourth quarter and fiscal year ended Dec. 31, 2021. The company also provided a business update and offered guidance on its strategic changes and growth acceleration planned for FY 2022. “The PCT and BaroFold technologies have provided important early opportunities for commercial traction, as PBI forged scientific understanding and acceptance for its high-pressure platforms,” Jeffrey N. Peterson, chairman of the PBI board, said in the press release. “Building on multiple peer-reviewed opinion leader scientific articles and presentations, accelerating instrument installations, and expanding paid research projects, these platforms are expected to generate important sales growth in 2022 and beyond. In addition, we believe the UST platform is opening up a new, game-changing growth trajectory with its promise for revolutionizing massive global markets from pharmaceuticals, nutraceuticals, cosmetics, agrochem, food/beverage processing, and more.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼